MYNEO THERAPEUTICS

A little history

myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.

myNEO offices

To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:

  • Development of state-of-the-art antigen prediction algorithms
  • Discovery of novel, dark antigen targets called camyotopes
  • (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
  • The publication of high-impact scientific papers
  • ISO and regulatory approval for clinical use of technology
  • Securing valuable intellectual property with multiple patents
  • Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
Jan Van den Berghe

Jan Van den Berghe

Co-founder

Jan is a serial entrepreneur in the food and biotech industry. Following his education in bioengineering, he worked as a senior consultant for the Boston Consulting Group and as an Independent Strategy Consultant.

Jan co-founded and served as director of Genohm, which was acquired by Agilent Technologies in 2018. Jan also served as Director and Chairman of Oystershell laboratories, a world-class developer of innovative consumer healthcare products. Jan obtained an MBA from INSEAD and a Master's in General Management from Vlerick Management School.

View LinkedIn profile